Molecular Discovery

Rectify Pharmaceuticals Appoints Robert Hughes as Executive Vice President, Drug Discovery and Preclinical Development, and Xiaobing Li as Chief Development Officer

Retrieved on: 
Thursday, October 6, 2022

Robert Hughes, Ph.D., recently joined as Executive Vice President of Drug Discovery and Preclinical Development and Xiaobing Li, Ph.D., joins as Chief Development Officer.

Key Points: 
  • Robert Hughes, Ph.D., recently joined as Executive Vice President of Drug Discovery and Preclinical Development and Xiaobing Li, Ph.D., joins as Chief Development Officer.
  • Xiaobing brings a wealth of experience in portfolio management and cross-functional program team leadership from discovery stages to NDA submission.
  • As Chief Development Officer, she will play a key role in driving the advancement of our Positive Functional Modulators (PFMs) from discovery through clinical development.
  • Previously, Dr. Hughes served as an entrepreneur-in-residence at Atlas Venture and Vice President, Head of Molecular Discovery at Disarm Therapeutics.

Octant Raises $80 Million Series B Round to Support Expansion of Next-Generation Drug Discovery Platform, Announces Collaboration with Bristol Myers Squibb and Key Appointments

Retrieved on: 
Thursday, April 21, 2022

In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.

Key Points: 
  • In addition to Catalio, the Series B financing included participation from Bristol Myers Squibb, and existing investors Andreessen Horowitz Bio Fund, Allen & Co., and 50 Years VC.
  • Octant also plans to develop multiple additional therapeutic programs in small molecule chaperone therapies for rare genetic diseases.
  • Immunogenetics and immunopharmacology are among the most complex areas in biology and drug discovery, with potential to impact countless patients, continued Kosuri.
  • As Chief Scientific Officer, Rick Artis will be responsible for Octant's chemistry function and drug discovery and development programs.

Ribon Therapeutics Announces Key Management Promotions

Retrieved on: 
Wednesday, September 1, 2021

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the promotions of Heike Keilhack, Ph.D., to Chief Scientific Officer and Kevin Kuntz, Ph.D., to Chief Drug Development Officer.
  • We have made significant progress advancing our clinical trial program for RBN-2397, developing RBN-3143 through IND-enabling studies and identifying additional NAD+-utilizing enzyme targets, said Heike Keilhack, Ph.D., Chief Scientific Officer, Ribon Therapeutics.
  • I am excited to take on the new role of CSO as we leverage our proprietary platform to discover first-in-mechanism therapeutics.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.